Mega Genomics Limited will seek shareholder approval at its Annual General Meeting (AGM) on 21 May 2026 for a series of ordinary resolutions covering board composition, dividend payout, auditor reappointment and refreshed capital mandates.

Dividend Proposal • A final dividend of RMB0.15 per share for FY-2025 is proposed. • Eligible shares total 197.03 million, excluding 27.27 million restricted shares, translating into an aggregate distribution of about RMB30.00 million. • The dividend will be declared in Renminbi and paid in Hong Kong dollars on 9 July 2026, based on the average PBoC RMB/HKD central parity rates for the five business days before the AGM. • Shareholders must be on the register by 29 May 2026; the books close from 28–29 May 2026.

Board Changes • Executive Directors Dr Yu Rong and Ms Lin Lin, Non-executive Director Ms Guo Meiling and Independent Non-executive Director Dr Zhang Ying will retire and stand for re-election. • The Nomination Committee recommends their re-appointment; independence criteria under Listing Rule 3.13 have been met for Dr Zhang.

Auditor Tenure • Crowe (HK) CPA Limited is nominated for reappointment with an expected fee of roughly RMB1.50 million for the next audit cycle.

Capital Management Mandates • Share Repurchase: Directors seek authority to repurchase up to 10% of issued shares (22.43 million shares) during the mandate period. • Share Issuance: A separate mandate would allow the issue, allotment or transfer of up to 20% of issued shares (44.86 million shares) and an additional mandate to extend this limit by the number of shares repurchased. • Both prior mandates granted on 28 June 2024 have expired.

Meeting Logistics • The AGM will be held at the company’s Beijing headquarters at 10:00 a.m. on 21 May 2026. • Shareholders must lodge proxy forms by 10:00 a.m. on 19 May 2026. • The register will be closed 18–21 May 2026 for AGM eligibility.

Share Structure Snapshot • As of 20 April 2026, Mega Genomics has 224.30 million issued shares, including 27.27 million restricted shares.

If all resolutions pass, Mega Genomics will reaffirm board stability, distribute cash to shareholders and maintain flexibility for future capital management through share issuance and buy-backs within prescribed limits.